Latest Ask the Experts

Biomarker Assays for Prostate Cancer Management

Should biomarker assays be an integral part of prostate cancer patient care?

Focal Therapy for Prostate Cancer: An Update

What are the major challenges regarding focal therapy for prostate cancer?

The New mCRPC Drugs

What have you learned about the differences in tolerability of the newer agents, adverse event profiles, and cost?

Latest Prostate Cancer News

Vasectomy Poses Minimal Risk of Prostate Cancer

Vasectomy Poses Minimal Risk of Prostate Cancer

Researchers calculated that the absolute increase in lifetime risk of prostate cancer associated with vasectomy was just 0.6%.

Active Surveillance for Intermediate-risk Prostate Cancer Challenged

Active Surveillance for Intermediate-risk Prostate Cancer Challenged

Study reveals that a quarter of men with low-volume intermediate-risk prostate cancer had adverse pathologic features found at radical prostatectomy.

Tall, Obese Men More Likely to Have Aggressive Prostate Cancer

Tall, Obese Men More Likely to Have Aggressive Prostate Cancer

Every additional 4 inches of height was associated with a 21% increase in risk of being diagnosed with high-grade prostate cancer, and a 17% increased risk of dying from prostate cancer.

RP for Prostate Cancer May Not Offer Survival Advantage

RP for Prostate Cancer May Not Offer Survival Advantage

Randomized trial found no significant difference in all-cause and cancer-specific survival between radical prostatectomy and observation for localized prostate cancer.

Decisional Regret Doesn't Vary by Tx in PCa

Decisional Regret Doesn't Vary by Tx in PCa

Across time, only African-American race correlated with greater regret.

Germline Mutations Up in PCa Patients With Another Primary Cancer

Germline Mutations Up in PCa Patients With Another Primary Cancer

Men with prostate cancer and at least one additional primary cancer are enriched for harboring a germline deleterious mutation in a cancer-predisposing gene.

Radical Prostatectomy Use for High-Risk Prostate Cancer Rises Sharply

Radical Prostatectomy Use for High-Risk Prostate Cancer Rises Sharply

Over a 10-year period, radical prostatectomy use increased steadily while radiotherapy use declined

Prostate Atrophy, Inflammation Associated With Lower PCa Risk

Prostate Atrophy, Inflammation Associated With Lower PCa Risk

Both findings on biopsy also predict a lower odds of high-grade cancer.

Negative Confirmatory Biopsy a Good Sign in Prostate Cancer AS

Negative Confirmatory Biopsy a Good Sign in Prostate Cancer AS

Prostate cancer patients on active surveillance who have no cancer found on confirmatory biopsy have a reduced risk of grade and volume reclassification.

PSA Testing in Controls of Screening Trial May Undermine Results

PSA Testing in Controls of Screening Trial May Undermine Results

Over 15 years of follow-up, considerable proportion of men undergo prostate-specific antigen testing

Novel Markers May Predict Prostate Cancer in Non-Black Men

Novel Markers May Predict Prostate Cancer in Non-Black Men

No added benefit was seen with the addition of biomarkers for African-American men.

Multimodal Therapy Found to Benefit Men With LN-positive PCa

Multimodal Therapy Found to Benefit Men With LN-positive PCa

New findings suggest that clinicians consider the pathologic characteristics of the primary tumor as well as the burden of LN metastases when deciding on management, investigators say.

Post-RP Radiotherapy Benefits Selected Men With Elevated PSA

Post-RP Radiotherapy Benefits Selected Men With Elevated PSA

Radiotherapy for prostate cancer patients with persistently elevated PSA after radical surgery improved survival only among those with worse pathologic characteristics.

High-income US Counties Have Higher Diagnoses of PCa

High-income US Counties Have Higher Diagnoses of PCa

High-income counties had far higher diagnosis rates for the four cancers than low-income counties, but the combined mortality rate was similar for both.

Survival Up With Patient-Reported Symptom Monitoring During Chemo

Survival Up With Patient-Reported Symptom Monitoring During Chemo

The researchers found that the median overall survival was 31.2 and 26.0 months in the PRO and usual care groups, respectively.

Sign up for free e-Newsletters